Q1 Earnings Estimate for TNGX Issued By HC Wainwright

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - HC Wainwright issued their Q1 2026 earnings estimates for shares of Tango Therapeutics in a report released on Monday, April 14th. HC Wainwright analyst R. Burns expects that the company will post earnings of ($0.39) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics' Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.40) EPS.

Tango Therapeutics Price Performance

Shares of NASDAQ TNGX traded up $0.01 during trading on Tuesday, hitting $1.29. The stock had a trading volume of 467,141 shares, compared to its average volume of 1,074,640. The company has a market capitalization of $139.46 million, a PE ratio of -1.09 and a beta of 1.03. The firm has a fifty day moving average of $1.79 and a two-hundred day moving average of $3.26. Tango Therapeutics has a 12 month low of $1.11 and a 12 month high of $12.02.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The firm had revenue of $4.12 million during the quarter, compared to the consensus estimate of $7.84 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TNGX. Dynamic Technology Lab Private Ltd bought a new position in shares of Tango Therapeutics during the fourth quarter valued at approximately $33,000. Stonebrook Private Inc. bought a new position in shares of Tango Therapeutics during the fourth quarter valued at $34,000. Ameriprise Financial Inc. purchased a new stake in shares of Tango Therapeutics during the fourth quarter valued at $35,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of Tango Therapeutics during the fourth quarter valued at $38,000. Finally, Squarepoint Ops LLC purchased a new position in Tango Therapeutics in the 4th quarter worth about $40,000. Institutional investors own 78.99% of the company's stock.

Insider Buying and Selling at Tango Therapeutics

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the completion of the transaction, the chief executive officer now owns 1,631,264 shares of the company's stock, valued at $4,877,479.36. The trade was a 0.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 24,268 shares of company stock worth $72,561 over the last three months. 6.30% of the stock is currently owned by insiders.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.